NKTX Nkarta, Inc.

NASDAQ
$1.12

Nkarta, Inc. (NKTX) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.45 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -30.4% since its last earnings release on November 5, 2026.

Nkarta Missed Consensus Estimates
Thursday, November 5, 2026 · 4:34 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:35 PM ET
Earnings Whisper
-
vs ($0.45)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.48

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nkarta, Inc.

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.